J. Anim Sci.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J. Anim Sci. 1987. 65:877-880.
© 1987 American Society of Animal Science

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Foster, A. G.
Right arrow Articles by Ericsson, G. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Foster, A. G.
Right arrow Articles by Ericsson, G. F.

Effect of Efrotomycin on Gain and Feed Efficiency for Pigs from Weaning until Market Weight1,2,3,

A. G. Foster, D. H. Baker4, T. R. Cline5, G. L. Cromwell6, T. L. Veum7, R. Alva-Valdes8 and G. F. Ericsson

Merck Sharp & Dohme Research Laboratories, Rahway, NJ 07065

Abstract

Six studies involving 700 pigs were conducted in five separate swine research facilities to evaluate weight gain and efficiency of feed utilization in pigs fed the antibiotic efrotomycin. Pigs averaging 8.4 kg at the beginning of the studies were fed fortified corn-soybean meal diets that contained efrotomycin at 0, 2, 4, 8 or 16 ppm for an average of 120 d to market weight, about 92.1 kg. Pigs fed efrotomycin gained 5.9 to 8.9% faster (P<.01) and were 1.7 to 4.0% more efficient (P<.01) than those fed control diets. The improvement in growth rate was linear from 2 through 16 ppm, while feed efficiency (gain/feed) plateaued at 4 ppm efrotomycin. Treatment x study interactions were not significant for average daily gain or feed efficiency, showing that the response to efrotomycin was similar in each study. These studies indicate that efrotomycin is effective in improving gain and efficiency of feed utilization in swine from weaning until market weight.


Footnotes

1 Studies supported in part by Merck Sharp & Dohme Res. Lab., Division of Merck & Co., Inc., Rahway, NJ 07065.

2 Efrotomycin is an investigational new animal drug that is not currently cleared by the Food and Drug Admin. for use in swine.

3 The authors gratefully acknowledge the following for assistance in the successful completion of these studies: M. S. Edmonds, Dept. of Anim. Sci., Univ. of Illinois; T. S. Stahly and H. J. Monegue, Dept. of Anim. Sci., Univ. of Kentucky; K. Watkins, Dept. of Anim. Sci., Univ. of Missouri and L. Underwood, Dept. of Anim. Sci., Purdue Univ.

4 Dept. of Anim. Sci., Univ. of Illinois, Urbana, IL 61801.

5 Dept. of Anim. Sci., Purdue Univ., West Lafayette, IN 47907.

6 Dept. of Anim. Sci., Univ. of Kentucky, Lexington, KY 40546.

7 Dept. of Anim. Sci., Univ. of Missouri, Columbia, MO 65211.

8 Merck Res. Farm, Fulton, MO 65251.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the American Society of Animal Science.